XenoPort, Inc. (NASDAQ:XNPT)

prodrugs get approval much more quickly than new drugs

XenoPort is biotech's version of Teen Mom. GSK impressed her with his shiny Dodge Charger and they collaborated in the back seat, which led to the birth of bouncing baby Horizant last year. GSK looked at Horizant and didn't see much of a facial resemblance, and wondered again about that friendship XenoPort had with that weird Japanese guy Astellas. GSK stopped taking Horizant on trips to the park and now he isn't returning XenoPort's calls anymore. Meanwhile, XenoPort's attempts to start new relationships seem to keep falling apart. The XP21279 thing looks to be belly up and if that dork arbaclofen doesn't cough up a ring at the end of the year, XenoPort might have to hit the pole to make ends meet.

Chart play

Below pre approval price?

just tracking

FDA

biotech comeback us technicals

strong buy

currently my fourth-largest position (see this post -> http://caps.fool.com/Blogs/biopharmaceuticals-xnpt/416742).

XNPT oversold by shorties.. Intrinsic value is $10-18.

This stock is likely to sky rocket from its current price of $8.16 within the next few weeks possibly a couple months. The reason behind this is because they just had a better than expected earnings report, and they have the funds to fund their future research. They also just need to revise their new restless leg drug to be able to get it approved by the FDA. This is definitely a bargain stock at the moment, and soon to be a very profitable stock.

fill the gap

oversold

It should be wait what FDA say for this REJECT.
And, we can do something for this company.
I am waiting for a while.
I believe what XNPT did well.

bizzounce

25US$ Feb 2011

Getting restless for a long - playing an anticipated FDA pop in February. Long at $18.82

from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.

Purely a value play. Doesn't deserve a 13% drop because Solzira's NDA has to be reformatted.